LB
Highly rated in
19
conditions
Highly rated in
19
conditions
Check Dr. Leslie S. Bradford's experience treating your condition:
About Dr. Leslie S. Bradford

Leslie Bradford is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Scarborough, Maine. Bradford has been practicing medicine for over 16 years and is highly rated in 19 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Salpingo-Oophorectomy, and Oophorectomy. She is licensed to treat patients in Massachusetts. Bradford is currently accepting new patients.

Her clinical research consists of co-authoring 31 peer reviewed articles and participating in 9 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Leslie S. Bradford it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Leslie S. Bradford accepts the following insurance:

  •  Ambetter
  •  Anthem

Call to see if your plan is accepted.
Locations
100 Campus Dr, Scarborough, ME 04074
Background & Education
Graduate Institution
University Of Vermont College Of Medicine, 2006
Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in MA
Hospital Affiliations
Frisbie Memorial Hospital
LincolnHealth - Miles Campus And Hospital
Mid Coast Hospital
Maine Medical Center
Northern Light Eastern Maine Medical Center
Southern Maine Health Care - Biddeford
Franklin Memorial Hospital
Stephens Memorial Hospital
Northern Light Inland Hospital
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


11 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
View 2 Less Clinical Trial -

31 Total Publications

In Reply.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors